R L Dunbar

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Slaying the metabolic syndrome. Are we battling the Hydra or the Chimera?
    R L Dunbar
    University of Pennsylvania Medical School, Philadelphia, PA, USA
    Minerva Endocrinol 29:89-111. 2004
  2. ncbi The unsung perils of peripheral arterial disease: a malady in search of a patient
    Richard L Dunbar
    University of Pennsylvania Medical School, Philadelphia, PA 19104, USA
    Prev Cardiol 8:108-13; quiz 114-5. 2005
  3. ncbi Demystifying triglycerides: a practical approach for the clinician
    Richard L Dunbar
    Cardiovascular Risk Intervention Program, University of Pennsylvania School of Medicine, Philadelphia, USA
    Cleve Clin J Med 72:661-6, 670-2, 674-5 passim. 2005
  4. ncbi Seeing red: flushing out instigators of niacin-associated skin toxicity
    Richard L Dunbar
    Department of Medicine, Division of Experimental Therapeutics, Institute for Translational Medicine and Therapeutics, Pennsylvania 19104, USA
    J Clin Invest 120:2651-5. 2010
  5. ncbi Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome
    John S Millar
    Departments of Pharmacology, University of Pennsylvania, 652 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Arterioscler Thromb Vasc Biol 29:140-6. 2009

Detail Information

Publications5

  1. ncbi Slaying the metabolic syndrome. Are we battling the Hydra or the Chimera?
    R L Dunbar
    University of Pennsylvania Medical School, Philadelphia, PA, USA
    Minerva Endocrinol 29:89-111. 2004
    ..We review the limited data available regarding metabolic syndrome, with a focus on expert opinion gleaned from clinical guidelines, and offer advice to the clinician from our own experience with this population...
  2. ncbi The unsung perils of peripheral arterial disease: a malady in search of a patient
    Richard L Dunbar
    University of Pennsylvania Medical School, Philadelphia, PA 19104, USA
    Prev Cardiol 8:108-13; quiz 114-5. 2005
    ..This article will review the relationship between PAD and other vascular disease, emphasizing the role of PAD in prevention efforts...
  3. ncbi Demystifying triglycerides: a practical approach for the clinician
    Richard L Dunbar
    Cardiovascular Risk Intervention Program, University of Pennsylvania School of Medicine, Philadelphia, USA
    Cleve Clin J Med 72:661-6, 670-2, 674-5 passim. 2005
    ..The third report of the National Cholesterol Education Program's Adult Treatment Panel (ATP-III) provides a much-needed strategy for managing patients with high triglycerides, based on the best available evidence...
  4. ncbi Seeing red: flushing out instigators of niacin-associated skin toxicity
    Richard L Dunbar
    Department of Medicine, Division of Experimental Therapeutics, Institute for Translational Medicine and Therapeutics, Pennsylvania 19104, USA
    J Clin Invest 120:2651-5. 2010
    ..These efforts bring us one step closer to solving a key limitation of an important cardioprotective drug and reveal that the skin response to niacin is much more complicated than previously thought...
  5. ncbi Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome
    John S Millar
    Departments of Pharmacology, University of Pennsylvania, 652 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Arterioscler Thromb Vasc Biol 29:140-6. 2009
    ..We sought to determine the effect of a potent and highly specific PPAR-alpha agonist, LY518674, on apoA-I, apoA-II, and apoB-100 kinetics in humans with metabolic syndrome and low levels of HDL cholesterol (C)...